Pathogenesis and clinical management of new-onset diabetes mellitus after distal pancreatectomy

Waili ALAPATI; Wei HAN

doi:10.12449/JCH250738

Volume 41 Issue 7

Jul. 2025

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2025 > 41(7): 1476-1480

PDF( 1468 KB)

Pathogenesis and clinical management of new-onset diabetes mellitus after distal pancreatectomy

DOI: 10.12449/JCH250738

Waili ALAPATI,
Wei HAN^{,
,}

Department of Pancreatic Surgery，The First Affiliated Hospital of Xinjiang Medical University，Urumqi 830000，China

Research funding:

National Natural Science Foundation of China (82360585)

More Information

Corresponding author: HAN Wei， 13999846637@139.com （ORCID： 0009-0008-8918-0525）
Received Date: 2024-11-10
Accepted Date: 2024-12-11
Published Date: 2025-07-25

Abstract

Abstract

Pancreatogenic diabetes is a special form of diabetes secondary to pancreatic diseases. Pancreatectomy is one of the main causes of pancreatogenic diabetes， with the highest incidence rate observed after distal pancreatectomy. Due to the high misdiagnosis rate of pancreatogenic diabetes and the increased risk of death and readmission in patients with pancreatogenic diabetes compared with those with type 2 diabetes， early accurate identification and diagnosis of pancreatogenic diabetes are of great importance for improving prognosis. This article systematically reviews the research advances in new-onset diabetes after distal pancreatectomy in terms of epidemiological features， risk factors， pathophysiological mechanism， diagnostic criteria， and treatment strategies， in order to provide a reference for clinical diagnosis， treatment， and scientific research.
- Pancreatectomy,
- Diabetes Mellitus,
- Risk Factors,
- Diagnosis,
- Therapeutics

FullText(HTML)

References(52)

References

[1]	American Diabetes Association Professional Practice Committee. 2. classification and diagnosis of diabetes: Standards of medical care in diabetes-2022[J]. Diabetes Care, 2022, 45( Suppl 1): S17- S38. DOI: 10.2337/dc22-S002.
[2]	SUN H, SAEEDI P, KARURANGA S, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045[J]. Diabetes Res Clin Pract, 2022, 183: 109119. DOI: 10.1016/j.diabres.2021.109119.
[3]	HARDT PD, BRENDEL MD, KLOER HU, et al. Is pancreatic diabetes(type 3c diabetes) underdiagnosed and misdiagnosed?[J]. Diabetes Care, 2008, 31( Suppl 2): S165- S169. DOI: 10.2337/dc08-s244.
[4]	WEI JL, OU YR, CHEN JT, et al. Mapping global new-onset, worsening, and resolution of diabetes following partial pancreatectomy: A systematic review and meta-analysis[J]. Int J Surg, 2024, 110( 3): 1770- 1780. DOI: 10.1097/JS9.0000000000000998.
[5]	WANG XJ, MISAWA R, ZIELINSKI MC, et al. Regional differences in islet distribution in the human pancreas: Preferential beta-cell loss in the head region in patients with type 2 diabetes[J]. PLoS One, 2013, 8( 6): e67454. DOI: 10.1371/journal.pone.0067454.
[6]	SACHS T, PRATT WB, CALLERY MP, et al. The incidental asymptomatic pancreatic lesion: Nuisance or threat?[J]. J Gastrointest Surg, 2009, 13( 3): 405- 415. DOI: 10.1007/s11605-008-0788-0.
[7]	YU JW, SUN R, HAN XL, et al. New-onset diabetes mellitus after distal pancreatectomy: A systematic review and meta-analysis[J]. J Laparoendosc Adv Surg Tech A, 2020, 30( 11): 1215- 1222. DOI: 10.1089/lap.2020.0090.
[8]	IMAMURA S, NIWANO F, BABAYA N, et al. High incidence of diabetes mellitus after distal pancreatectomy and its predictors: A long-term follow-up study[J]. J Clin Endocrinol Metab, 2024, 109( 3): 619- 630. DOI: 10.1210/clinem/dgad634.
[9]	CHEN ZH, SHI N, XING C, et al. A novel clinical model for risk prediction and stratification of new-onset diabetes mellitus after distal pancreatectomy[J]. Hepatobiliary Surg Nutr, 2023, 12( 6): 868- 881. DOI: 10.21037/hbsn-22-382.
[10]	FIRKINS SA, HART PA, PORTER K, et al. Incidence and risk factors for new-onset diabetes mellitus after surgical resection of pancreatic cystic lesions: A MarketScan study[J]. Pancreas, 2022, 51( 5): 427- 434. DOI: 10.1097/MPA.0000000000002054.
[11]	SERA N, NAKAMURA T, HORIE I, et al. Characteristics of patients who developed glucose intolerance in the early period after partial pancreatectomy[J]. Diabetol Int, 2021, 12( 1): 140- 144. DOI: 10.1007/s13340-020-00440-y.
[12]	TARIQ M, JAJJA MR, MAXWELL DW, et al. Diabetes development after distal pancreatectomy: Results of a 10 year series[J]. HPB(Oxford), 2020, 22( 7): 1034- 1041. DOI: 10.1016/j.hpb.2019.10.2440.
[13]	MAXWELL DW, JAJJA MR, GALINDO RJ, et al. Post-pancreatectomy diabetes index: A validated score predicting diabetes development after major pancreatectomy[J]. J Am Coll Surg, 2020, 230( 4): 393- 402. e 3. DOI: 10.1016/j.jamcollsurg.2019.12.016.
[14]	SHIRAKAWA S, MATSUMOTO I, TOYAMA H, et al. Pancreatic volumetric assessment as a predictor of new-onset diabetes following distal pancreatectomy[J]. J Gastrointest Surg, 2012, 16( 12): 2212- 2219. DOI: 10.1007/s11605-012-2039-7.
[15]	DAI MH, XING C, SHI N, et al. Risk factors for new-onset diabetes mellitus after distal pancreatectomy[J]. BMJ Open Diab Res Care, 2020, 8( 2): e001778. DOI: 10.1136/bmjdrc-2020-001778.
[16]	YAMADA D, TAKAHASHI H, ASUKAI K, et al. Investigation of the influence of pancreatic surgery on new-onset and persistent diabetes mellitus[J]. Ann Gastroenterol Surg, 2021, 5( 4): 575- 584. DOI: 10.1002/ags3.12435.
[17]	NGUYEN A, DEMIRJIAN A, YAMAMOTO M, et al. Development of postoperative diabetes mellitus in patients undergoing distal pancreatectomy versus Whipple procedure[J]. Am Surg, 2017, 83( 10): 1050- 1053.
[18]	HAMAD A, HYER JM, THAYAPARAN V, et al. Pancreatogenic diabetes after partial pancreatectomy: A common and understudied cause of morbidity[J]. J Am Coll Surg, 2022, 235( 6): 838- 845. DOI: 10.1097/XCS.0000000000000360.
[19]	KANG JS, JANG JY, KANG MJ, et al. Endocrine function impairment after distal pancreatectomy: Incidence and related factors[J]. World J Surg, 2016, 40( 2): 440- 446. DOI: 10.1007/s00268-015-3228-9.
[20]	SHEN JL, CAO JS, HE J, et al. Clinical utility of resected pancreatic volume ratio calculation for predicting postoperative new-onset diabetes mellitus after distal pancreatectomy-a propensity-matched analysis[J]. Heliyon, 2023, 9( 5): e15998. DOI: 10.1016/j.heliyon.2023.e15998.
[21]	SHINGYOJI A, MIKATA R, OGASAWARA S, et al. Diverse transitions in diabetes status during the clinical course of patients with resectable pancreatic cancer[J]. Jpn J Clin Oncol, 2020, 50( 12): 1403- 1411. DOI: 10.1093/jjco/hyaa136.
[22]	NIWANO F, BABAYA N, HIROMINE Y, et al. Three-year observation of glucose metabolism after pancreaticoduodenectomy: A single-center prospective study in Japan[J]. J Clin Endocrinol Metab, 2022, 107( 12): 3362- 3369. DOI: 10.1210/clinem/dgac529.
[23]	MATVEYENKO AV, BUTLER PC. Relationship between beta-cell mass and diabetes onset[J]. Diabetes Obes Metab, 2008, 10 Suppl 4( 4): 23- 31. DOI: 10.1111/j.1463-1326.2008.00939.x.
[24]	de BRUIJN KM, van EIJCK CH. New-onset diabetes after distal pancreatectomy: A systematic review[J]. Ann Surg, 2015, 261( 5): 854- 861. DOI: 10.1097/sla.0000000000000819.
[25]	KING J, KAZANJIAN K, MATSUMOTO J, et al. Distal pancreatectomy: Incidence of postoperative diabetes[J]. J Gastrointest Surg, 2008, 12( 9): 1548- 1553. DOI: 10.1007/s11605-008-0560-5.
[26]	MAO YS, ZHAO XF, ZHOU LH, et al. Evaluating perioperative glycemic status after different types of pancreatic surgeries via continuous glucose monitoring system: A pilot study[J]. Gland Surg, 2021, 10( 10): 2945- 2955. DOI: 10.21037/gs-21-495.
[27]	KLOVER PJ, MOONEY RA. Hepatocytes: Critical for glucose homeostasis[J]. Int J Biochem Cell Biol, 2004, 36( 5): 753- 758. DOI: 10.1016/j.biocel.2003.10.002.
[28]	LEE BW, KANG HW, HEO JS, et al. Insulin secretory defect plays a major role in the development of diabetes in patients with distal pancreatectomy[J]. Metabolism, 2006, 55( 1): 135- 141. DOI: 10.1016/j.metabol.2005.08.005.
[29]	FUKUDA T, BOUCHI R, TAKEUCHI T, et al. Importance of intestinal environment and cellular plasticity of islets in the development of postpancreatectomy diabetes[J]. Diabetes Care, 2021, 44( 4): 1002- 1011. DOI: 10.2337/dc20-0864.
[30]	KIM-MULLER JY, FAN J, KIM YJR, et al. Aldehyde dehydrogenase 1a3 defines a subset of failing pancreatic β cells in diabetic mice[J]. Nat Commun, 2016, 7: 12631. DOI: 10.1038/ncomms12631.
[31]	SLEZAK LA, ANDERSEN DK. Pancreatic resection: Effects on glucose metabolism[J]. World J Surg, 2001, 25( 4): 452- 460. DOI: 10.1007/s002680020337.
[32]	AHRÉN B. Glucagon secretion in relation to insulin sensitivity in healthy subjects[J]. Diabetologia, 2006, 49( 1): 117- 122. DOI: 10.1007/s00125-005-0056-8.
[33]	HENKEL E, MENSCHIKOWSKI M, KOEHLER C, et al. Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus[J]. Metabolism, 2005, 54( 9): 1168- 1173. DOI: 10.1016/j.metabol.2005.03.024.
[34]	SCHRADER H, MENGE BA, BREUER TGK, et al. Impaired glucose-induced glucagon suppression after partial pancreatectomy[J]. J Clin Endocrinol Metab, 2009, 94( 8): 2857- 2863. DOI: 10.1210/jc.2009-0826.
[35]	DINIĆ S, ARAMBAŠIĆ JOVANOVIĆ J, USKOKOVIĆ A, et al. Oxidative stress-mediated beta cell death and dysfunction as a target for diabetes management[J]. Front Endocrinol(Lausanne), 2022, 13: 1006376. DOI: 10.3389/fendo.2022.1006376.
[36]	LONYAI A, KODAMA S, BURGER D, et al. The promise of Hox11+ stem cells of the spleen for treating autoimmune diseases[J]. Horm Metab Res, 2008, 40( 2): 137- 146. DOI: 10.1055/s-2007-1022560.
[37]	DIEGUEZ-ACUNA FJ, GYGI SP, DAVIS M, et al. Splenectomy: A new treatment option for ALL tumors expressing Hox-11 and a means to test the stem cell hypothesis of cancer in humans[J]. Leukemia, 2007, 21( 10): 2192- 2194. DOI: 10.1038/sj.leu.2404927.
[38]	PARK S, HONG SM, AHN IS. Can splenocytes enhance pancreatic β-cell function and mass in 90% pancreatectomized rats fed a high fat diet?[J]. Life Sci, 2009, 84( 11-12): 358- 363. DOI: 10.1016/j.lfs.2008.12.022.
[39]	YOU L, YAO L, MAO YS, et al. Partial pancreatic tail preserving subtotal pancreatectomy for pancreatic cancer: Improving glycemic control and quality of life without compromising oncological outcomes[J]. World J Gastrointest Surg, 2020, 12( 12): 491- 506. DOI: 10.4240/wjgs.v12.i12.491.
[40]	ANDERSSON AK, FLODSTRÖM M, SANDLER S. Cytokine-induced inhibition of insulin release from mouse pancreatic beta-cells deficient in inducible nitric oxide synthase[J]. Biochem Biophys Res Commun, 2001, 281( 2): 396- 403. DOI: 10.1006/bbrc.2001.4361.
[41]	BÖNI-SCHNETZLER M, BOLLER S, DEBRAY S, et al. Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I[J]. Endocrinology, 2009, 150( 12): 5218- 5229. DOI: 10.1210/en.2009-0543.
[42]	DONATH MY. Targeting inflammation in the treatment of type 2 diabetes: Time to start[J]. Nat Rev Drug Discov, 2014, 13( 6): 465- 476. DOI: 10.1038/nrd4275.
[43]	PONDUGALA PK, SASIKALA M, GUDURU VR, et al. Interferon-γ decreases nuclear localization of pdx-1 and triggers β-cell dysfunction in chronic pancreatitis[J]. J Interferon Cytokine Res, 2015, 35( 7): 523- 529. DOI: 10.1089/jir.2014.0082.
[44]	HUANG H, DONG X, KANG MX, et al. Novel blood biomarkers of pancreatic cancer-associated diabetes mellitus identified by peripheral blood-based gene expression profiles[J]. Am J Gastroenterol, 2010, 105( 7): 1661- 1669. DOI: 10.1038/ajg.2010.32.
[45]	EWALD N, BRETZEL RG. Diabetes mellitus secondary to pancreatic diseases(Type 3c): Are we neglecting an important disease?[J]. Eur J Intern Med, 2013, 24( 3): 203- 206. DOI: 10.1016/j.ejim.2012.12.017.
[46]	HART PA, BELLIN MD, ANDERSEN DK, et al. Type 3c(pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer[J]. Lancet Gastroenterol Hepatol, 2016, 1( 3): 226- 237. DOI: 10.1016/S2468-1253(16)30106-6.
[47]	KANG MJ, JUNG HS, JANG JY, et al. Metabolic effect of pancreatoduodenectomy: Resolution of diabetes mellitus after surgery[J]. Pancreatology, 2016, 16( 2): 272- 277. DOI: 10.1016/j.pan.2016.01.006.
[48]	BELLIN MD. Pancreatogenic diabetes in children with recurrent acute and chronic pancreatitis: Risks, screening, and treatment(mini-review)[J]. Front Pediatr, 2022, 10: 884668. DOI: 10.3389/fped.2022.884668.
[49]	MAKUC J. Management of pancreatogenic diabetes: Challenges and solutions[J]. Diabetes Metab Syndr Obes, 2016, 9: 311- 315. DOI: 10.2147/DMSO.S99701.
[50]	LI DH, TANG HW, HASSAN MM, et al. Diabetes and risk of pancreatic cancer: A pooled analysis of three large case-control studies[J]. Cancer Causes Control, 2011, 22( 2): 189- 197. DOI: 10.1007/s10552-010-9686-3.
[51]	LÖHR JM, DOMINGUEZ-MUNOZ E, ROSENDAHL J, et al. United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis(HaPanEU)[J]. United European Gastroenterol J, 2017, 5( 2): 153- 199. DOI: 10.1177/2050640616684695.
[52]	CRAVALHO CKL, MEYERS AG, MABUNDO LS, et al. Metformin improves blood glucose by increasing incretins independent of changes in gluconeogenesis in youth with type 2 diabetes[J]. Diabetologia, 2020, 63( 10): 2194- 2204. DOI: 10.1007/s00125-020-05236-y.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1) / Tables(1)

Get Citation

PDF

XML

Article Metrics

Article views (392) PDF downloads(23)

Pathogenesis and clinical management of new-onset diabetes mellitus after distal pancreatectomy

DOI: 10.12449/JCH250738

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Pathogenesis and clinical management of new-onset diabetes mellitus after distal pancreatectomy

DOI: 10.12449/JCH250738

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content